quinuclidines has been researched along with olanzapine in 17 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (29.41) | 29.6817 |
| 2010's | 10 (58.82) | 24.3611 |
| 2020's | 2 (11.76) | 2.80 |
| Authors | Studies |
|---|---|
| Navari, RM; Province, PS | 1 |
| Navari, RM | 2 |
| Herrstedt, J | 1 |
| Chowhan, N; Einhorn, LH; Hanna, NH; Johnson, CS; Loehrer, PJ; McClean, J; Navari, RM; Passik, SD; Vinson, J | 1 |
| Ellebaek, E; Herrstedt, J | 1 |
| Gray, SE; Nagy, CK; Navari, RM | 1 |
| Wang, SY; Yang, ZJ; Zhang, L | 1 |
| Abe, M; Hihara, H; Hirakawa, T; Hirashima, Y; Ichikawa, Y; Ito, K; Itonaga, Y; Kado, N; Kasamatsu, Y; Komeda, S; Kuji, S; Miyagi, K; Murakami, J; Nasu, K; Takahashi, N; Takekuma, M; Tanaka, A | 1 |
| Asano, C; Haegawa, I; Horio, Y; Kadowaki, S; Kajita, M; Komori, A; Maeda, A; Mizutani, A; Muro, K; Narita, Y; Nomura, M; Oze, I; Taniguchi, H; Ura, T; Yoshida, T | 1 |
| Alice K, P; Badyal, D; Kwatra, G; Mukhopadhyay, S | 1 |
| Barras, M; Butler, JP; Curley, C; Kennedy, GA; Nakagaki, M | 1 |
| Isobe, T; Iwamoto, Y; Kaneko, M; Kenmotsu, H; Kikugawa, M; Koizumi, S; Mori, K; Murakami, H; Naito, T; Nakashima, K; Nishiyama, F; Omori, S; Ono, A; Takahashi, T; Wakuda, K; Yokoyama, K | 1 |
| Cao, D; Kang, B; Meng, Y; Ning, H; Wang, H; Xie, S | 1 |
| Arai, T; Hashimoto, H; Iwasa, S; Minato, K; Nagashima, K; Nakao, M; Nakayama, T; Ohyanagi, F; Sakai, H; Shimada, Y; Suzuki, K; Takeda, K; Takiguchi, T; Terakado, H; Yamamoto, N; Yanai, T | 1 |
| Deng, C; Lian, J | 1 |
| Deng, C; Han, M; Lian, J; Su, Y | 1 |
5 review(s) available for quinuclidines and olanzapine
| Article | Year |
|---|---|
Emerging drugs for chemotherapy-induced emesis.
Topics: Antiemetics; Antineoplastic Agents; Antipsychotic Agents; Aprepitant; Benzodiazepines; Brain; Dexamethasone; Drug Therapy, Combination; Gastrointestinal Tract; Humans; Isoquinolines; Morpholines; Nausea; Neurokinin-1 Receptor Antagonists; Olanzapine; Palonosetron; Quinuclidines; Randomized Controlled Trials as Topic; Receptors, Neurokinin-1; Receptors, Serotonin, 5-HT3; Serotonin 5-HT3 Receptor Antagonists; Serotonin Antagonists; Vagus Nerve; Vomiting | 2006 |
Prevention of emesis from multiple-day and high-dose chemotherapy regimens.
Topics: Antiemetics; Antineoplastic Agents; Benzodiazepines; Drug Therapy, Combination; Humans; Isoquinolines; Metoclopramide; Neurokinin-1 Receptor Antagonists; Olanzapine; Palonosetron; Quinuclidines; Serotonin 5-HT3 Receptor Antagonists; Serotonin Antagonists; Vomiting | 2007 |
[Medical treatment of chemotherapy-induced nausea and vomiting].
Topics: Antiemetics; Antineoplastic Agents; Aprepitant; Benzodiazepines; Dexamethasone; Drug Interactions; Drug Therapy, Combination; Evidence-Based Medicine; Ghrelin; Glucocorticoids; Granisetron; Humans; Isoquinolines; Morpholines; Nausea; Neurokinin-1 Receptor Antagonists; Olanzapine; Palonosetron; Peptide Hormones; Practice Guidelines as Topic; Quinuclidines; Serotonin Antagonists; Vomiting | 2007 |
Optimizing antiemetic therapy in multiple-day and multiple cycles of chemotherapy.
Topics: Antiemetics; Antineoplastic Agents; Aprepitant; Benzodiazepines; Cisplatin; Dexamethasone; Dopamine D2 Receptor Antagonists; Drug Administration Schedule; Humans; Isonipecotic Acids; Isoquinolines; Morpholines; Nausea; Neurokinin-1 Receptor Antagonists; Olanzapine; Palonosetron; Quinuclidines; Serotonin 5-HT3 Receptor Antagonists; Serotonin Antagonists; Vomiting | 2008 |
Olanzapine for preventing nausea and vomiting induced by moderately and highly emetogenic chemotherapy.
Topics: Antiemetics; Antineoplastic Agents; Aprepitant; Benzodiazepines; Dexamethasone; Emetics; Humans; Isoquinolines; Morpholines; Nausea; Neoplasms; Neurokinin-1 Receptor Antagonists; Olanzapine; Palonosetron; Quinuclidines; Vomiting | 2014 |
8 trial(s) available for quinuclidines and olanzapine
| Article | Year |
|---|---|
A phase II trial of olanzapine, dexamethasone, and palonosetron for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier oncology group study.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Benzodiazepines; Dexamethasone; Female; Humans; Isoquinolines; Male; Middle Aged; Nausea; Neoplasms; Olanzapine; Outcome Assessment, Health Care; Palonosetron; Quinuclidines; United States; Vomiting | 2007 |
The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Aprepitant; Benzodiazepines; Cisplatin; Cyclophosphamide; Dexamethasone; Double-Blind Method; Doxorubicin; Female; Humans; Isoquinolines; Male; Metoclopramide; Middle Aged; Morpholines; Nausea; Neoplasms; Olanzapine; Palonosetron; Quinuclidines; Vomiting | 2013 |
Efficacy and safety of olanzapine combined with aprepitant, palonosetron, and dexamethasone for preventing nausea and vomiting induced by cisplatin-based chemotherapy in gynecological cancer: KCOG-G1301 phase II trial.
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Benzodiazepines; Cisplatin; Dexamethasone; Female; Genital Neoplasms, Female; Humans; Isoquinolines; Male; Middle Aged; Morpholines; Nausea; Olanzapine; Palonosetron; Prospective Studies; Quinuclidines; Serotonin Antagonists; Vomiting | 2016 |
A phase II trial of prophylactic olanzapine combined with palonosetron and dexamethasone for preventing nausea and vomiting induced by cisplatin.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Benzodiazepines; Cisplatin; Dexamethasone; Drug Therapy, Combination; Female; Humans; Isoquinolines; Male; Middle Aged; Nausea; Olanzapine; Palonosetron; Quinuclidines; Vomiting | 2016 |
Role of olanzapine in chemotherapy-induced nausea and vomiting on platinum-based chemotherapy patients: a randomized controlled study.
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Benzodiazepines; Dexamethasone; Female; Humans; Isoquinolines; Male; Middle Aged; Nausea; Olanzapine; Organoplatinum Compounds; Palonosetron; Quality of Life; Quinuclidines; Vomiting | 2017 |
A randomized trial of olanzapine versus palonosetron versus infused ondansetron for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients undergoing hematopoietic stem cell transplantation.
Topics: Adolescent; Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Benzodiazepines; Drug-Related Side Effects and Adverse Reactions; Female; Hematopoietic Stem Cell Transplantation; Humans; Isoquinolines; Male; Middle Aged; Nausea; Olanzapine; Ondansetron; Palonosetron; Prospective Studies; Quinuclidines; Transplantation Conditioning; Treatment Outcome; Vomiting; Young Adult | 2017 |
A Phase II study of palonosetron, aprepitant, dexamethasone and olanzapine for the prevention of cisplatin-based chemotherapy-induced nausea and vomiting in patients with thoracic malignancy.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Aprepitant; Benzodiazepines; Cisplatin; Dexamethasone; Female; Humans; Isoquinolines; Male; Middle Aged; Morpholines; Nausea; Olanzapine; Palonosetron; Quinuclidines; Thoracic Neoplasms; Vomiting | 2017 |
A double-blind randomized phase II dose-finding study of olanzapine 10 mg or 5 mg for the prophylaxis of emesis induced by highly emetogenic cisplatin-based chemotherapy.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Aprepitant; Benzodiazepines; Cisplatin; Dexamethasone; Double-Blind Method; Female; Humans; Isoquinolines; Male; Middle Aged; Morpholines; Neoplasms; Olanzapine; Palonosetron; Quinuclidines; Treatment Outcome; Vomiting | 2018 |
4 other study(ies) available for quinuclidines and olanzapine
| Article | Year |
|---|---|
5-HT3 receptors as important mediators of nausea and vomiting due to chemotherapy.
Topics: Antiemetics; Antineoplastic Agents; Benzodiazepines; Dexamethasone; Half-Life; Humans; Isoquinolines; Nausea; Neoplasms; Neurokinin-1 Receptor Antagonists; Olanzapine; Palonosetron; Quality of Life; Quinuclidines; Receptors, Neurokinin-1; Receptors, Serotonin, 5-HT3; Serotonin 5-HT3 Receptor Antagonists; Vomiting | 2015 |
Effects of haloperidol, olanzapine, ziprasidone, and PHA-543613 on spatial learning and memory in the Morris water maze test in naïve and MK-801-treated mice.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Bridged Bicyclo Compounds, Heterocyclic; Disease Models, Animal; Haloperidol; Male; Maze Learning; Memory; Mice; Mice, Inbred C57BL; Olanzapine; Piperazines; Quinuclidines; Schizophrenia; Spatial Learning; Thiazoles; Treatment Outcome | 2017 |
The dosage-dependent effects of cevimeline in preventing olanzapine-induced metabolic side-effects in female rats.
Topics: Adipose Tissue; Adiposity; Animals; Behavior, Animal; Blood Glucose; Dose-Response Relationship, Drug; Drug Interactions; Eating; Female; Locomotion; Metabolic Syndrome; Olanzapine; Open Field Test; Quinuclidines; Rats; Rats, Sprague-Dawley; Receptor, Muscarinic M3; Thiophenes; Treatment Outcome; Triglycerides; Weight Gain | 2020 |
Cevimeline co-treatment attenuates olanzapine-induced metabolic disorders via modulating hepatic M3 muscarinic receptor: AMPKα signalling pathway in female rats.
Topics: AMP-Activated Protein Kinases; Animals; Antipsychotic Agents; Female; Liver; Metabolic Diseases; Muscarinic Agonists; Olanzapine; Quinuclidines; Rats; Rats, Sprague-Dawley; Receptor, Muscarinic M3; Signal Transduction; Thiophenes; Weight Gain | 2022 |